MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Experimental therapeutics"

  • 2019 International Congress

    Using cognitive computing to identify existing drugs with potential to stabilize mitophagy pathways associated with Parkinson’s Disease

    N. Visanji, N. Moskal, G. Shi, A. Lacoste, S. Spangler, P. Lewis, A. Mcquibban (Toronto, ON, Canada)

    Objective: We applied IBM Watson for Drug Discovery (WDD), a cognitive computing platform that uses natural language processing, to identify compounds with the potential to…
  • 2019 International Congress

    The mGlu2/3 orthosteric antagonist LY-341,495 abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset

    A. Hamadjida, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

    Objective: We seek to determine the effect of orthosteric blockade of metabotropic glutamate 2 and 3 (mGlu2/3) receptors with LY-341,495 on the anti-dyskinetic and anti-psychotic…
  • 2018 International Congress

    Therapeutic exposures of CX-8998, a potent, selective and state dependent Cav3 channel antagonist in development for Essential Tremor and Parkinson’s disease Tremor in Cav3 driven neurological models

    M. Lee, E. Newbold, S. Papapetropoulos (Cambridge, MA, USA)

    Objective: In this study, we utilized preclinical data to establish predicted human therapeutic exposures of the potent, selective and state-dependent Cav3 channel antagonist, CX-8998, currently…
  • 2018 International Congress

    Motor and cognitive deficits in a mouse model of tauopathy with tau isoforms imbalance: Potential therapeutic strategies

    ME. Avale, SL. Espindola, A. Damianich, M. Sartor, J. Ferrario (Buenos Aires, Argentina)

    Objective: This work investigates motor phenotypes and neurochemical changes in a mouse model of tauopathy linked to tau mis-splicing. We sought to validate a potential…
  • 2018 International Congress

    A Phase 2 Efficacy Study of CX-8998, a Potent and Selective T-Type Calcium (Cav3) Modulator in Parkinson’s disease Tremor (PDT) Patients: Design and Dose-Selection Rationale

    S. Papapetropoulos, M. Lee, S. Boyer, M. Versavel (Cambridge, MA, USA)

    Objective: The objective of this study is to access the efficacy of CX-8998 using the MDS-UPDRS Tremor Score (MDS-UPDRS-TS) and a digital biomarker platform, while…
  • 2018 International Congress

    Trans-spinal direct current stimulation for managing primary orthostatic tremor

    J.C. Lamy, P. Varriale, E. ApartiS, Z. Kosutzka, E. Roze, M. Vidailhet (Paris, France)

    Objective: To evaluate in a randomized, double-blind, sham-controlled, crossover trial the efficacy of non-invasive trans-spinal direct current stimulation (tsDCS) for managing primary orthostatic tremor (POT).…
  • 2018 International Congress

    Design and Status of the BIIB054 SPARK Trial

    Parkinson Study Group, A. Siderowf (NY, USA)

    Objective: To describe the design and status of the BIIB054 SPARK trial of the safety and potential efficacy of a monoclonal antibody (mAb) targeting alpha-synuclein…
  • 2018 International Congress

    Tetrahydroisoquinoline Molecule Identified in Traditional Ayurveda Medicine Modulates Inflammation in MPTP Mice

    R. Banerjee, R. Paidi, P. Jaisankar, K. Mohanakumar, S. Biswas (Kolkata, India)

    Objective: Potential ‘Anti-parkinsonian’ activity of a tetrahydroisoquinoline (TIQ) molecule of traditional ‘Ayurveda’ medicine was tested in a preclinical MPTP mice model for Parkinson’s disease (PD).…
  • 2018 International Congress

    Proof-of-Principle Quantitative EEG Study of CX-8998, an Oral, Potent and Selective T-Type Calcium antagonist in development for symptomatic treatment of Essential Tremor and Parkinson’s disease Tremor

    S. Papapetropoulos, M. Lee, S. Boyer (Cambridge, MA, USA)

    Objective: To study the pharmacodynamics (PD) of CX-8998, using pharmaco-electroencephalography (phEEG) and define plasma concentrations of CX-8998 which are pharmacologically active on objective CNS parameters.…
  • 2018 International Congress

    Partial depletion of peripheral M1 macrophages ameliorates the neuroinflammation and dopaminergic neuronal death in the brain of a MPTP-induced mouse model of PD

    A. Yan, Y. Zhang, J. Lin, L. Song, X. Wang, Z. Liu (Shanghai, China)

    Objective: Neuroinflammation in the PD brain involves the activation of microglia and the increasing levels of inflammatory cytokines. Several studies have shown that the peripheral…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #28970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley